Press releases - CF PharmTech

Search

CN

Press releases

Home · News · Press releases ·

Press releases

SCROLL DOWN

Press releases

Press releases

20

2025.10
Breaking

Applicable for children Aged 3 and Above! CF PharmTech 's Mometasone Furoate Nasal Spray, a First-Line Treatment for Allergic Rhinitis, Files for Market Approval

28

Share

$Breaking<br \><br \>Applicable for children Aged 3 and Above! CF PharmTech 's Mometasone Furoate Nasal Spray, a First-Line Treatment for Allergic Rhinitis, Files for Market Approval$
20

2025.10
Good News

CF PharmTech (2652.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange

32

Share

$Good News<br \><br \>CF PharmTech (2652.HK) Successfully Lists on the Main Board of the Hong Kong Stock Exchange$
23

2025.09
CF Overseas

Entering the 2.0 Era of Innovation and Globalization - CF’s Inhalation Preparations Make Successful Overseas Debut!

31

Share

$CF Overseas<br \><br \>Entering the 2.0 Era of Innovation and Globalization - CF’s Inhalation Preparations Make Successful Overseas Debut!$
23

2025.09
Good News

CF Successfully Passes EU QP Audit; Its Quality Management System Gains International Recognition

30

Share

$Good News<br \><br \>CF Successfully Passes EU QP Audit; Its Quality Management System Gains International Recognition$
23

2025.09
Good News

CF Successfully Passes On-Site Inspection by Overseas Regulatory Authorities

27

Share

$Good News<br \><br \>CF Successfully Passes On-Site Inspection by Overseas Regulatory Authorities$
17

2022.11
Good News | CF PharmTech won the "Best Employer of Greater Suzhou" in 2022

9615

Share

On November 17, 2022, the 9th "Best Employers in Greater Suzhou" was officially announced by Suzhou Industrial Park Human Resources Development Co., LTD. With excellent human resource management pract
07

2022.11
Good news from CF PharmTech | The first domestic blockbuster product for the treatment of allergic rhinitis - Azelastine Hydrochloride and Fluticasone Propionate Nasal Spray (ShuFeiMin ®) was approved

9170

Share

Today, CF PharmTech, Inc. (hereinafter referred to as: "CF PharmTech") independently developed the heavy product ShuFeiMin® (National drug approval number: H20223778, general
25

2022.07
Announcement of the receipt of the listing notice to
CF PharmTech, Inc.

8098

Share
03

2020.07
CF PharmTech has completed F round of 360 million yuan equity investment to support rapid development of domestic high-end inhalation products.

8241

Share

CF PharmTech, Inc. (CF PharmTech, Inc., referred to as "CF PharmTech"), following the completion of the E round of 630 million financing in January, once again completed the F round of 360 million yuan financing, a total of nearly 1 billion financing with